Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Алкогольная болезнь печени

Список литературы

  1. http://www.euro.who.int/ru/health-topics/disease-prevention/alcohol-use/publications/2017/who-alcohol-brief-intervention-training-manual-for-primary-care-2017
  2. В.Т. Ивашкин, М.В. Маевская, Ч.С. Павлов, Ю.П. Сиволап, В.Д. Луньков, М.С. Жаркова, Р.В. Масленников. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Рос журн гастроэнтерол гепатол колопроктол 2017;27(6):20-40
  3. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease // J. Hepatol. 2018; 69:154-181.
  4. Kim D.K., Kim Y.H., Jang H.H. Estrogen-related receptor γ controls hepatic CB1 receptor-mediated CYP2E1 expression and oxidative liver injury by alcohol // Gut. 2013. No62(7). Р. 1044-1054. doi:10.1136/gutjnl-2012-303347.
  5. Болезни печени и желчевыводящих путей: Руководство для врачей / Под ред. В.Т. Ивашкина – 2-е изд. ООО «Издат. Дом «М-Вести», 2005. – 536 с.
  6. Алкогольно-вирусные заболевания печени / Ивашкин В.Т., Маевская М.В. – М.: Литтерра, 2007 – 160 с.]. Болезни печени и желчевыводящих путей: Руководство для врачей / Под ред. В.Т. Ивашкина – 2-е изд. ООО «Издат. Дом «М-Вести», 2005. – 536 с.
  7. Bellentani S., Saccoccio G., Costa G., Tiribelli C., Manenti F., Sodde M., et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. // Gut. – 1997. – Vol.41. - No6. – P. 845–850.
  8. Hart C.L., Morrison D.S., Batty G.D., Mitchell R.J., Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. // BMJ. – 2010. – Vol.340. – P. 1240.
  9. Kennedy O.J., Roderick P., Buchanan R., Fallowfield J.A., Hayes P.C., Parkes J. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. // Alimentary Pharmacology & Therapeutics. – 2016. – Vol.43. – P.562–574.
  10. Chan L.N., Anderson G.D. Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol)//Clin Pharmacokinet. 2014. N 53(12). P. 1115 – 36. doi: 10.1007/s40262-014-0190-x.
  11. Sandahl T.D., Jepsen P., Thomsen K.L., Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: a nationwide population based cohort study. // Journal of Hepatology. – 2011. – Vol.54. – P. 760–764
  12. Rehm J., Gmel Sr G.E., Gmel G., Hasan O.S.M., Imtiaz S., Popova S., et al. The relationship between different dimensions of alcohol use and the burden of disease-an update. // Addiction. – 2017. – Vol.112. – P. 968–1001.
  13. Askgaard G., Gronbaek M., Kjaer M.S., Tjonneland A., Tolstrup J.S. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohortstudy. // Journal of Hepatology. - 2015. – Vol.62. - No5. – P.1061–1067.
  14. Aberg F., Helenius-Hietala J., Puukka P., Jula A. Binge drinking and the risk of liver events: A population-based cohort study. // Liver International. – 2017. - No37. – P. 1373–1381.
  15. Askgaard G., Leon D.A., Kjaer M.S., Deleuran T., Gerds T.A., Tolstrup J.S. Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study. // Hepatology. – 2017. – Vol. 65. – No3. - P. 929–937. 
  16. Dam M.K., Flensborg-Madsen T., Eliasen M., Becker U., Tolstrup J.S. Smoking and risk of liver cirrhosis: a population-based cohort study. // Scandinavian Journal of Gastroenterology. – 2013. – Vol.48. – No5. - P. 585–591.
  17. Tilg H. Cytokines in alcoholic and nonalcoholic steatohepatitis / Tilg H, Diehl AM. // N Engl J Med. – 2000. – Vol. 343. – p. 1467–1476.
  18. McClain C, Hill D, Song Z, et al. S-adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol 2002; 27:185-92.
  19. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev 2012; 92:1515-42.
  20. Purohit V, Abdelmalek M, Barve S, et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: Summary of a symposium. Am J Clin Nutr 2007; 86:14-24.
  21. Colell A, Garcia-Ruiz C, Miranda M, et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 1998; 115:1541-51.
  22. WHO Global status report on noncommunicable diseases 2014. // WHO Library Cataloguing-in-Publication Data. - 2014.
  23. Thursz, Mark et al., EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. // Journal of Hepatology. – 2018 – Vol.69., No1., P.154 – 181.
  24. Маевская М.В., Бакулин И.Г., Чирков А.А., Люсина Е.О, Луньков В.Д. Злоупотребление алкоголем среди пациентов гастроэнтерологического профиля. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2016 – Т.26 - No4. – С. 24-35.
  25. https://mednet.ru/images/news/docs/%D0%9F%D0%BE%D1%82%D1%80%D0%B5%D0%B1%D0%BB%D0%B5%D0%BD%D0%B8%D0%B5%20%D0%B8%20%D0%BF%D1%80%D0%BE%D0%B4%D0%B0%D0%B6%D0%B8%20%D0%B0%D0%BB%D0%BA%D0%BE%D0%B3%D0%BE%D0%BB%D1%8F%20%D0%B2%202018-2020%20%D0%B3%D0%B3.pdf
  26. Маевская М.В.  Алкогольная болезнь печени / М. В. Маевская // Клинические перспективы в гастроэнтерологии, гепатологии. – 2001. –№1. – с. 4-8.
  27. Ивашкин В.Т., Маевская М.В., Жаркова М.С., Жигалова С.Б., Киценко Е.А., Манукьян Г.В., Трухманов А.С., Маев И.В., Тихонов И.Н., Деева Т.А. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по диагностике и лечению фиброза и цирроза печени и их осложнений. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(6):56-102.
  28. Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: A Danish population-based cohort study. Hepatology 2010; 51:1675-82.
  29. Bell H, Jahnsen J, Kittang E, et al. Long-term prognosis of patients with alcoholic liver cirrhosis: A 15-year follow-up study of 100 Norwegian patients admitted to one unit. Scand J Gastroenterol 2004; 39:858-63.
  30. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. // Addiction. – 1993. – Vol.88. – P. 791–804.
  31. Babor T.F., Higgins-Biddle J.C., Saunders J.B., Monterio M.G. The Alcohol Use Disorders Identification Test, Guidelines for Use in Primary Care, second edition. // World Health Organization Department of Mental Health and Substance Dependence. 2nd edition. Geneva – 2001.     
  32. Spithoff S., Kahan M. Primary care management of alcohol use disorder and at-risk drinking: Part 1: screening and assessment. // Canadian Family Physician. – 2015. – Vol.61. - No6. – P. 509-514.
  33. Adams W.L., Barry K.L., Fleming M.F. Screening for problem drinking in older primary care patients. // JAMA. – 1996. - No276. – P. 1964–1967.
  34. Bradley K.A., Bush K.R., Epler A.J., et al. Two brief alcohol- creening tests from the Alcohol Use Disorders Identification Test (AUDIT): Validation in a female veterans affairs patient population. // Archive of Internal Medicine. – 2003. - Vol.163. - No6., P. 821-829.
  35. Cara Torruellas, Samuel W. French, Valentina Medici. Diagnosis of alcoholic liver disease//World J Gastroenterol. 2014. N 20(33). P. 11684-11699. doi: 10.3748/wjg.v20.i33.11684.
  36. Lee H. A. et al. Direct bilirubin is more valuable than total bilirubin for predicting prognosis in patients with liver cirrhosis //Gut and Liver. – 2021. – Т. 15. – №. 4. – С. 599.
  37. Кишкун А.А. Лабораторные маркеры алкоголизма (обзор литературы). Клин лабор диагн 2008;11:3-8 [Kishkun A.A. Laboratory markers of addiction to alcohol (review of literature). Klin labor diagn 2008; 11:3-8.
  38. Mammen E. F. Coagulation abnormalities in liver disease //Hematology/oncology clinics of North America. – 1992. – Т. 6. – №. 6. – С. 1247-1257.     
  39. Violi F. et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis //Gastroenterology. – 1995. – Т. 109. – №. 2. – С. 531-539.
  40. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. NephronClinPract 2012;120:c179–c184.
  41. Willmann. Ultrasound Elastography: Review of Techniques and Clinical Applications//Theranostics. 2017. N 7(5). P. 1303-1329. doi: 10.7150/thno.18650.
  42. Nguyen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, Mueller S, de Ledinghen V,Stärkel P, Gyune Kim S, Fernandez M, Madsen B, Naveau S, Krag A, Perlemuter G, Ziol M, Chatelain D, Diouf M. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018 Sep; 3(9): 614-625. doi: 10.1016/S2468-1253(18)30124-9.
  43. Grace Lai-Hung Wong. Update of liver fibrosis and steatosis with transient elastography (Fibroscan)//Gastroenterol Rep (Oxf). 2013. N 1(1). P. 19-26. doi: 10.1093/gastro/got007.
  44. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology 2015 vol. 63 j 237–264.
  45. EASL CPG: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2021; 73(3): 659-689.
  46. Maddrey W.C., Boitnott J.K., Bedine M.S., et al. Corticosteroid therapy of alcoholic hepatitis. // Gastroenterology. – 1978. – Vol.75. – No2. - P. 193–199.]. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. // Hepatology. – 2005. – Vol.41. – No2. - P. 353.  
  47. Mathurin P., Abdelnour M., Ramond M.J., Carbonell N., Fartoux L., Serfaty L., etal. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. // Hepatology. – 2003. – Vol.38. – P.1363–1369.
  48. Gong A., Leitold S., Uhanova J. et al. Predicting Pre-transplant Abstinence in Patients with Alcohol-Induced Liver Disease // Clin. Invest. Med. 2018. No41(2). Р. E37-E42. doi: 10.25011/cim.v41i2.29913.
  49. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. J Hepatol 2012; 57:399-420.
  50. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy, J of Hepatology, 2022.
  51. Amodio P. Hepatic encephalopathy: diagnosis and management. Liver Int 2018;38:966–975.
  52. Alvarez M.A., Cirera I., Solà R., et al. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. // Journal of Clinical Gastroenterology. – 2011. – Vol.45. - No10. – P. 906.
  53. Borowsky S.A., Strome S., Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. // Gastroenterology. – 1981. – Vol.80. – P.1405. 
  54. Xie Y., Feng B., Gao Y. and Wei L. Alcohol abstinence and survival. // Hepatology Research. - 2014. – Vol.44. – P. 436-449.
  55. Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol. 2014; 20(25): 8018 – 23. doi: 10.3748/wjg.v20.i25.8018.
  56. Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255–260. doi: 10.1136/gut.2010.224097.
  57. Arab JP, Díaz LA, Baeza N, et al. Identification of optimal therapeutic window  for steroid use in severe alcohol-associated hepatitis: a worldwide study. J Hepatol 2021;75:1026-33.
  58. Tkachenko P., Maevskaya M., Pavlov A. Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis. Hepatol Int 2016 June; DOI 10.1007/s12072-016-9751-4.
  59. Mato J.M., Camara J., Fernandez de Paz J. et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30:1081-9.
  60. Butterworth R. F. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis //Metabolic brain disease. – 2020. – Т. 35. – №. 1. – С. 75-81.
  61. Butterworth R. F. et al. Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta-analysis of randomized controlled trials //Journal of clinical and experimental hepatology. – 2018. – Т. 8. – №. 3. – С. 301-313.
  62. Jain A. et al. L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial //Hepatology. – 2022. – Т. 75. – №. 5. – С. 1194-1203.
  63. Уваров И. А. РОЛЬ ПРЕПАРАТА ГЕПА-МЕРЦ (L-ОРНИТИНА-L-АСПАРТАТА) В КОМПЛЕКСНОМ ЛЕЧЕНИИ АЛКОГОЛЬНОГО ДЕЛИРИЯ //Вопросы наркологии. – 2009. – №. 3. – С. 35-43.
  64. Mahpour NY, Pioppo-Phelan L, Reja M, Tawadros A, Rustgi VK. Pharmacologic Management of Hepatic Encephalopathy. Clin Liver Dis. 2020 May; 24(2): 231-242. doi: 10.1016/j.cld.2020.01.005.
  65. Минушкин О.Н., Фролова А.А., Шиндина Т.С. и др. Урсодезоксихолевая кислота в гастроэнтерологической практике. РМЖ. Медицинское обозрение. 2018;26(1(I)):18-22.
  66. Gilles Pelletier, Dominique Roulot, Thierry Davion et al. A Randomized Controlled Trial of Ursodeoxycholic Acid in Patients With Alcohol-Induced Cirrhosis and Jaundice. HEPATOLOGY, 2003, 887-892.
  67. Ivashkin, Vladimir T., et al. "Open-label Study of Ademetionine for the Treatment of Intrahepatic Cholestasis Associated With Alcoholic Liver Disease." Minerva Gastroenterologica E Dietologica, vol. 64, no. 3, 2018, pp. 208-219.
  68. В.В. Стельмах, И.Г. Бакулин, А.Л. Коваленко,  В.К. Козлов. Эффективность Ремаксола у пациентов с алкогольной болезнью печени. Экспериментальная и клиническая фармакология. 2022 6(85): 25-31. doi: 10.52420/2071-5943-2022-85-6-25-31.
  69. Винникова М.А., Уткин С.И., Ненастьева А.Ю., Захаров М.В. Эффективность включения ремаксола в терапию алкогольного абстинентного синдрома. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(1):40‑46.
  70. Луньков В.Д. диссертация на соискание к.м.н. Оптимизация прогноза пациента с алкогольной болезнью печени. Москва, 2021. https://www.sechenov.ru/upload/iblock/31c/Dissertatsiya-Lunkova-V.D..pdf?ysclid=ldoatrm1jl41789332.
  71. Sassi F., et al., Tackling Harmful Alcohol Use: Economics and Public Health Policy. // OECD report. -2015.
  72. Jonas DE, Garbutt JC, Amick HR, Brown JM, Brownley KA, Council CL, et al. Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2012;157:645–654.
  73. O’Donnell A, Anderson P, Newbury-Birch D, Schulte B, Schmidt C, Reimer J, et al. The impact of brief alcohol interventions in primary healthcare: a systematic review of reviews. Alcohol Alcohol 2014;49:66–78 http://www.talkingalcohol.com/files/pdfs/WHO_audit.pdf.
  74. Kaner E.F.S., Beyer F.R., Muirhead C., Campbell F., Pienaar E.D., Bertholet N.,Daeppen J.B., Saunders J.B., Burnand B. Effectiveness of brief alcohol interventions in primary care populations. // Cochrane Database of Systematic Reviews. – 2018. – Vol.2. - NoCD004148.
  75. Khan A., Tansel A., White D.L., et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease – a systematic review. //Clinical Gastroenterology and Hepatology. – 2016. – Vol.14. – P. 4
  76. Лазебник Л.Б., Голованова Е.В., Еремина Е.Ю., Кривошеев А.Б., Сас Е.И., Тарасова Л.В., Трухан Д.И., Хлынова О.В., Цыганова Ю.В. Алкогольная болезнь печени (АБП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020; 174(2): 4-28. DOI: 10.31146/1682-8658-ecg-174-2-4-28.
  77. Castera L., Pauwels A., Levy V. G. Prognostic indicators in patients with liver cirrhosis admitted to an intensive care unit //Gastroenterologie clinique et biologique. – 1996. – Т. 20. – №. 3. – С. 63-268.       
  78. Pessione F., Ramond M.J., Peters L., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. // Liver International. – 2003. – P. 23 - 45.
  79. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J; ELITA; ELTR Liver Transplant Centers. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010 Jan;10(1):138-48. doi: 10.1111/j.1600-6143.2009.02869.x. Epub 2009 Dec 1. PMID: 19951276.
  80. Murray KF, Carithers RL, Jr AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–1432. doi: 10.1002/hep.20704.
  81. Matsuoka L, Izzy M, Feurer ID, Rega SA, Ziogas IA, Alexopoulos SP. Sex and Gender Disparities in Pretransplant Characteristics and Relationships with Postoperative Outcomes in Liver Transplant Recipients with Alcoholic Liver Disease. Exp Clin Transplant. 2020 Nov;18(6):701-706. doi: 10.6002/ect.2020.0063. Epub 2020 Jun 16. PMID: 32552631.
  82. КР «Цирроз и фиброз печени» ID 715, https://cr.minzdrav.gov.ru/schema/715_1.
  83. Пропедевтика внутренних болезней. Учебник. 2-е издание, переработанное и дополненное. Ивашкин В.Т. “ГЭОТАР-Медиа”. 2023. 936 стр.
  84. Wang C, Gao H, Liu W, Chen J, Guo Y, Zhao P. Alcoholic cardiomyopathy in patients with alcoholic liver cirrhosis: a study across 10 years. Eur J Gastroenterol Hepatol. 2023 May 1;35(5):600-603. Doi: 10.1097/MEG.0000000000002541. Epub 2023 Mar 18. PMID: 36966758.
  85. Lu W, Wang NF. [Clinical classification and characteristics of alcoholic myocardial injury]. Zhonghua Yi Xue Za Zhi. 2019 Nov 5;99(41):3237-3242. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2019.41.008. PMID: 31694119.
  86. Schoppet M, Maisch B. Alcohol and the heart. Herz. 2001 Aug;26(5):345-52. Doi: 10.1007/pl00002037. PMID: 11556162.
  87. Armstrong PR, Ring É, MacNicholas R. A decade of rising alcoholic liver disease hospital admissions and deaths in Irish hospitals, 2007-2016: a retrospective cross-sectional analysis. Eur J Gastroenterol Hepatol. 2022 Jun 1;34(6):671-677. doi: 10.1097/MEG.0000000000002339. Epub 2022 Jan 4. PMID: 34985049.
  88. Bamnodkar K, Bamnodkar K, Khanvilkar Y. Study of Renal Dysfunction in Alcoholic Liver Disease. J Assoc Physicians India. 2023 Jan;71(1):1. PMID: 37116033.
  89. Rigopoulou EI, Gatselis N, Arvaniti P, Koukoulis GK, Dalekos GN. Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. Eur J Intern Med. 2021 Mar;85:86-91. doi: 10.1016/j.ejim.2020.12.024. Epub 2021 Jan 12. PMID: 33451888.
  90. Надинская М.Ю., Маевская М.В., Бакулин И.Г., Бессонова Е.Н., Буеверов А.О., Жаркова М.С., Оковитый С.В., Островская А.С., Гуляева К.А., Ивашкин В.Т. Диагностическое и прогностическое значение гипераммониемии у пациентов с циррозом печени, печеночной энцефалопатией и саркопенией (соглашение специалистов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(1):85-100. https://doi.org/10.22416/1382-4376-2024-34-1-85-100.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*